Systematic review: Does gastro-oesophageal reflux disease progress?

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 1, 2006, Pages 33-45

  Fullard, M ^a   Kang, J Y ^a   Neild, P ^a   Poullis, A ^a   Maxwell, J D ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; REMISSION; REVIEW; SYSTEMATIC REVIEW;

DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 33745169300     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02963.x     Document Type: Review

References (60)

1. Klauser AG Schindlbeck NE Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990 335 : 205 8.
2. Fass R Fennerty MB Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001 96 : 303 14.
3. Lundell LR Dent J Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999 45 : 172 80.
4. Rath HC Timmer A Kunkel C, et al. Comparison of interobserver agreement for different scoring systems for reflux esophagitis: impact of level of experience. Gastrointest Endosc 2004 60 : 44 9.
5. Eggleston A Wigerinck A Huijghebaert S Dubois D Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998 42 : 13 6.
6. Locke GR III. Talley NJ Fett SL Zinsmeister AR Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997 112 : 1448 56.
7. Diaz-Rubio M Moreno-Elola-Olaso C Rey E Locke GR III. Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 2004 19 : 95 105.
8. Mohammed I Nightingale P Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther 2005 21 : 821 7.
9. Ho KY Kang JY Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998 93 : 1816 22.
10. Ruigomez A Garcia Rodriguez LA Wallander MA Johansson S Graffner H Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharmacol Ther 2004 20 : 751 60.
11. Louis E DeLooze D Deprez P, et al. Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources. Eur J Gastroenterol Hepatol 2002 14 : 279 84.
12. Cameron AJ Zinsmeister AR Ballard DJ Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990 99 : 918 22.
13. Ronkainen J Aro P Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005 129 : 1825 31.
14. Newnham A Quinn MJ Babb P Kang JY Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment Pharmacol Ther 2003 17 : 665 76.
15. Lagergren J Bergstrom R Lindgren A Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 825 31.
16. Lagergren J. Oesophageal cancer and gastro-oesophageal reflux: what is the relationship Gut 2004 53 : 1064 5.
17. Shaheen NJ Crosby MA Bozymski EM Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus Gastroenterology 2000 119 : 333 8.
18. Hage M Siersema PD van Dekken H Steyerberg EW Dees J Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004 39 : 1175 9.
19. Anderson LA Murray LJ Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003 52 : 1081 4.
20. Watson A Heading RC Shepherd NA. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. A report of the working party of the British Society of Gastroenterology. http://www.bsg.org.uk
21. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002 97 : 1888 95.
22. Rubenstein JH Inadomi JM. Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol 2006 40 : 109 15.
23. Pace F Porro GB. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004 99 : 946 9.
24. Fass R Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework Am J Gastroenterol 2002 97 : 1901 9.
25. Quigley EM. Gastro-oesophageal reflux disease-spectrum or continuum QJM 1997 90 : 75 8.
26. National Institute of Clinical Excellence UK. NICE Guidelines for Management of Dyspepsia in Adults in Primary Care. http://www.nice.org.uk
27. Pace F Santalucia F Bianchi PG. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991 32 : 845 8.
28. Pace F Bollani S Molteni P Bianchi PG. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis 2004 36 : 111 5.
29. Isolauri J Luostarinen M Isolauri E Reinikainen P Viljakka M Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997 92 : 37 41.
30. McDougall NI Johnston BT Collins JS McFarland RJ Love AH. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 1997 9 : 1161 7.
31. Schindlbeck NE Klauser AG Berghammer G Londong W Muller-Lissner SA. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992 33 : 1016 9.
32. Kuster E Ros E Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994 35 : 8 14.
33. Bajbouj M Reichenberger J Neu B, et al. A prospective multicenter clinical and endoscopic follow-up study of patients with gastroesophageal reflux disease. Z Gastroenterol 2005 43 : 1303 7.
34. Garrido SA Guerrero Igea FJ Lepe Jimenez JA Perianes HC. Clinical features and endoscopic progression of gastroesophageal reflux disease. Rev Esp Enferm Dig 2003 95 : 712 16.
35. Behar J Sheahan DG Biancani P Spiro HM Storer EH. Medical and surgical management of reflux esophagitis. A 38-month report of a prospective clinical trial. N Engl J Med 1975 293 : 263 8.
36. Manabe N Yoshihara M Sasaki A Tanaka S Haruma K Chayama K. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002 17 : 949 54.
37. Sontag SJ O'Connell S Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003 98 : 987 99.
38. Brossard E Monnier P Ollyo J-B. Serious complications - stenosis, ulcers and Barrett's epithelium - develop in 21.6% of patients with erosive reflux oesophagitis. Gastroenterology 1991 100 : A36.
39. Ollyo J-B Monnier P Fontolliet C Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993 3 ( Suppl. 3 10.
40. Spechler SJ Lee E Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001 285 : 2331 8.
41. Abu FN. Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. J Gastroenterol 2003 38 : 1042 8.
42. Wetscher GJ Gadenstaetter M Klingler PJ, et al. Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease. Ann Surg 2001 234 : 627 32.
43. Klinkenberg-Knol EC Nelis F Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000 118 : 661 9.
44. El-Serag HB Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 1997 41 : 594 9.
45. Kulig M Nocon M Vieth M, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004 57 : 580 9.
46. Labenz J Jaspersen D Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol 2004 99 : 1652 6.
47. Cameron AJ Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992 103 : 1241 5.
48. Calabrese C Bortolotti M Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005 100 : 537 42.
49. Calabrese C Fabbri A Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003 18 : 525 32.
50. Sabesin SM Berlin RG Humphries TJ Bradstreet DC Walton-Bowen KL Zaidi S. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med 1991 151 : 2394 400.
51. Mee AS Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996 10 : 757 63.
52. Begg CB Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989 81 : 107 15.
53. Smith EB. Effect of investigator bias on clinical trials. Arch Dermatol 1989 125 : 216 8.
54. Kang JY. Systematic review: Geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004 20 : 705 17.
55. Bate CM Booth SN Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group. Gut 1995 36 : 492 8.
56. Dent J Hetzel DJ MacKinnon MA Reed WD Narielvala FM. Evaluation of omeprazole in reflux oesophagitis. Scand J Gastroenterol Suppl 1989 166 : 76 82.
57. Weston AP Badr AS Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. Am J Gastroenterol 1999 94 : 3420 6.
58. Clouse RE Richter JE Heading RC Janssens J Wilson JA. Functional esophageal disorders. Gut 1999 45 ( Suppl. 2 II31 6.
59. Meining A Ott R Becker I, et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only - what is the clinical significance Gut 2004 53 : 1402 7.
60. Bytzer P Havelund T Hansen JM. Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol 1993 28 : 119 25.